Markoczy, Z. Et Al. 2018. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. BMC CANCER , vol.18 .

Markoczy, Z., Sarosi, V., Kudaba, I., Galffy, G., Turay, U. Y., DEMİRKAZIK, A., ... Purkalne, G.(2018). Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. BMC CANCER , vol.18.

Markoczy, Zsolt Et Al. "Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial," BMC CANCER , vol.18, 2018

Markoczy, Zsolt Et Al. "Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial." BMC CANCER , vol.18, 2018

Markoczy, Z. Et Al. (2018) . "Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial." BMC CANCER , vol.18.

@article{article, author={Zsolt Markoczy Et Al. }, title={Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial}, journal={BMC CANCER}, year=2018}